,,ii #aahth ,,congress #ast ,session ,s4 #aifa ,,in ,,the ,,senate ,,of ,,the ,,united ,,states ,june #ac1 #bjbc,mr4 ,peters 7for himself and ,ms4 ,ernst7 introduced the following bill2 which was read twice and referred to the ,committee on ,health1 ,education1 ,labor1 and ,pensions ,a ,,bill ,to require an interagency risk assessment of the pharmaceutical supply chain to identify and mitigate health and national security risks1 and for other purposes4 #a4 ,short title ,this ,act may be cited as the ,pharmaceutical ,supply ,chain ,risk ,assessment ,act of #bjbc4 #b4 ,risk assessment 7a7 ,in general ,the ,secretary of ,health and ,human ,services shall lead1 in coordination with the ,secretary of ,defense1 the ,secretary of ,homeland ,security1 and the ,director of the ,office of ,pandemic ,preparedness and ,response ,policy1 a comprehensive risk assessment of the ,united ,states pharmaceutical supply chain and report to the relevant committees of ,congress on the findings of each such assessment4 ,the assessment shall be completed not later than #ah months after the date of enactment of this ,act1 and shall be updated annually thereafter4 7b7 ,contents ,at a minimum1 the risk assessment under subsection 7a7 shall-- 7#a7 use1 as applicable1 any drugs from the essential medicines list developed by the ,food and ,drug ,administration in response to ,executive ,order #acidd 7#he ,fed4 ,reg4 #diibi7 and any other relevant assessments or lists1 as appropriate1 to identify1 in coordination with the private sector1 a list of essential medicines1 to be updated regularly on a timeframe that the ,secretary of ,health and ,human ,services1 in coordination with the ,secretary of ,defense and the ,secretary of ,homeland ,security1 determines appropriate1 which shall include the active pharmaceutical ingredients and drugs that-- 7,a7 are reasonably likely to be required to respond to a public health emergency or to a chemical1 biological1 radiological1 or nuclear threat2 or 7,b7 the shortage of which would pose a significant threat to the ,united ,states health care system or at-risk populations2 7#b7 identify1 for each of the active pharmaceutical ingredients and drugs that are identified under paragraph 7#a7-- 7,a7 the active pharmaceutical ingredients and drugs with vulnerable supply chains2 7,b7 the amount manufactured by each establishment registered under section #eaj7;b7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cfj7;b771 as reported under section #eaj7;j77#c7 of such ,act 7#ba ,u4,s4,c4 #cfj7;j77#c771 or1 with respect to any active pharmaceutical ingredient or drug for which such information is unavailable1 an explanation for why the information is unavailable2 7,c7 the drugs that are sourced either exclusively or primarily from foreign establishments1 including drugs manufactured domestically from active pharmaceutical ingredients sourced exclusively or primarily from foreign establishments2 and 7,d7 the active pharmaceutical ingredients that are sourced either exclusively or primarily from foreign establishments2 7#c7 assess key starting materials and excipients used in manufacturing the active pharmaceutical ingredients and drugs identified under paragraph 7#a72 7#d7 assess current domestic manufacturing capabilities with respect to drugs 7including key starting materials1 excipients1 and active pharmaceutical ingredients7 identified under paragraph 7#a71 including advanced manufacturing capabilities2 7#e7 identify critical vulnerabilities1 including cybersecurity threats2 7#f7 identify the existing statutory authorities the ,department of ,defense1 the ,department of ,health and ,human ,services1 and the ,department of ,homeland ,security have to address public health or national security risks that may arise as a result of vulnerabilities in the pharmaceutical supply chain2 and 7#g7 identify any deficiencies1 lack of authorities1 or limitations in policy or process that limit the ability of any of the departments described in paragraph 7#f7 to address vulnerabilities in the pharmaceutical supply chain identified in the risk assessment1 and describe the plans of the departments described in paragraph 7#f7 to mitigate such vulnerabilities4 7c7 ,publication of assessment ,the risk assessment under subsection 7a7 7including any updates7 shall be publicly available in an unclassified form but may include a classified annex containing any information that the ,secretary of ,health and ,human ,services determines to be sensitive4 7d7 ,definitions ,in this section3 7#a7 ,advanced manufacturing ,the term advanced manufacturing has the meaning given the term advanced and continuous pharmaceutical manufacturing in section #cjaf7;h7 of the #bast ,century ,cures ,act 7#ba ,u4,s4,c4 #cii;h7h774 7#b7 ,cybersecurity threat ,the term cybersecurity threat has the meaning given such term in section #bbjj of the ,homeland ,security ,act of #bjjb 7#f ,u4,s4,c4 #fej74 7#c7 ,drug ,the term drug has the meaning given such term in section #bja7;g7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cba7;g774 7#d7 ,relevant committees of congress ,the term relevant committees of ,congress means the ,committee on ,homeland ,security and ,governmental ,affairs1 the ,committee on ,health1 ,education1 ,labor1 and ,pensions1 and the ,committee on ,armed ,services of the ,senate and the ,committee on ,homeland ,security1 the ,committee on ,energy and ,commerce1 and the ,committee on ,armed ,services of the ,house of ,representatives4 7e7 ,clarification ,the participation of the ,secretary of ,health and ,human ,services in developing and updating the list of essential medicines under subsection 7b77#a7 shall be deemed to be full satisfaction of the requirements applicable to such secretary under section #c of ,executive ,order #acidd 7#he ,fed4 ,reg4 #diibi74